vimarsana.com

Page 2 - கேம்பிரிட்ஜ் நிறுவனம் ஆஃப் சிகிச்சை நோயெதிர்ப்பு தொற்று நோய் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Covid variants and vaccine resistance: all you need to know

Covid variants and vaccine resistance: all you need to know Sarah Boseley © Provided by The Guardian Photograph: Brain light/Alamy The Oxford/AstraZeneca vaccine is the mainstay of the UK government’s immunisation plans and vital globally. Will it work against the variant of the virus that emerged in South Africa? A study carried out by Oxford and Astra Zeneca together with the University of Witwatersrand in South Africa shows that it does not protect people infected with the variant against mild to moderate Covid, but the researchers believe it will still prevent severe illness, hospitalisation and death. The study involved more than 2,000 people with an average age of 31, which means they were relatively young and at lower risk. So scientists cannot yet be certain the protection remains against serious disease, but they think it’s likely.

South africaUnited kingdomShabir madhiOxford astrazenecaSarah gilbertRavi guptaCambridge institute of therapeutic immunology infectious diseaseOxford universityUniversity of the witwatersrandUniversity of witwatersrandGuardian photographCambridge instituteTherapeutic immunologyInfectious diseaseProf ravi guptaAlamy scientists

Likelihood of severe and long COVID may be established very early on following infection

Date Time Likelihood of severe and ‘long’ COVID may be established very early on following infection New research provides important insights into the role played by the immune system in preventing – and in some cases increasing the severity of – COVID-19 symptoms in patients. It also finds clues to why some people experience ‘long COVID’. Our evidence suggests that the journey to severe COVID-19 may be established immediately after infection, or at the latest around the time that they begin to show symptoms Paul Lyons Among the key findings, which have not yet been peer-reviewed, are: Individuals who have asymptomatic or mild disease show a robust immune response early on during infection.

United kingdomLaura bergamaschiKen smithPaul lyonsJohn bradleyUnited kingdom research innovationCambridge institute of therapeutic immunology infectious diseaseAddenbrooke charitableCambridge biomedical research centreImmunology consortiumUniversity of cambridgeCambridge university hospitalsCambridge instituteTherapeutic immunologyInfectious diseaseChief investigator

vimarsana © 2020. All Rights Reserved.